Josiane E. Eid
YOU?
Author Swipe
View article: High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation
High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation Open
The term chondrosarcoma refers to a rare and heterogeneous group of malignant cartilaginous tumors that are typically resistant to chemotherapy and radiotherapy. Metastatic chondrosarcoma has a poor prognosis, and effective systemic therap…
View article: Data from Targeting the Wnt Pathway in Synovial Sarcoma Models
Data from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Synovial sarcoma is an aggressive soft-tissue malignancy of children and young adults, with no effective systemic therapies. Its specific oncogene, SYT–SSX (SS18–SSX), drives sarcoma initiation and development. The exact mechanism of SYT–S…
View article: Supplementary Figure S1 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S1 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S1 - PDF file 554K, Breeding strategy used to generate beta-catenin-null SYT-SSX2 transgenic mice
View article: Supplementary Figure S8 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S8 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S8 - PDF file 1084K, Figure S8: Effects of SSTC-104 on Wnt-regulated tissues
View article: Supplementary Methods and Legends from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Methods and Legends from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Methods and Legends - PDF file 130K, Methods:Additional information on experimental techniques Legends: describing supplementary figures
View article: Supplementary Figure S9 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S9 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S9 - PDF file 867K,Figure S9: The SYT-SSX2 domain SSXRD executes �-catenin activation and myogenic differentiation
View article: Supplementary Figures S4 - S7 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figures S4 - S7 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figures S4, S5, S6, S7 - PDF file 1832K, Figure S4:Pyrvinium effect on beta-catenin in SYT-SSX2 expressing C2C12 and synovial sarcoma cells Figure S5:Phosphorylated �-catenin and full-length APC in HS-SY-II and SYO-1 SS cells…
View article: Supplementary Figure S9 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S9 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S9 - PDF file 867K,Figure S9: The SYT-SSX2 domain SSXRD executes �-catenin activation and myogenic differentiation
View article: Supplementary Figures S2 and S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figures S2 and S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figures S2 and S3 - PDF file 2332K, Figure S2:SG3 tumors are positive for beta-catenin and Myf5 Figure S3:Normal development of Myf5 myoblasts in beta-catenin knockout mice
View article: Supplementary Figure S11 and Tables S1-S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S11 and Tables S1-S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S11 and Tables S1-S3 - PDF file 460K, Figure S11: Regulation of an embryonic Wnt-interactive network by SYT-SSX2 and in human synovial sarcomas Table S1: Differentially regulated Wnt components in mesenchymal precursor…
View article: Supplementary Figure S10 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S10 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S10 4882K, Figure S10a and S10b: Nuclear beta-catenin accumulation in human synovial sarcoma tumors
View article: Data from Targeting the Wnt Pathway in Synovial Sarcoma Models
Data from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Synovial sarcoma is an aggressive soft-tissue malignancy of children and young adults, with no effective systemic therapies. Its specific oncogene, SYT–SSX (SS18–SSX), drives sarcoma initiation and development. The exact mechanism of SYT–S…
View article: Supplementary Figures S2 and S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figures S2 and S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figures S2 and S3 - PDF file 2332K, Figure S2:SG3 tumors are positive for beta-catenin and Myf5 Figure S3:Normal development of Myf5 myoblasts in beta-catenin knockout mice
View article: Supplementary Methods and Legends from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Methods and Legends from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Methods and Legends - PDF file 130K, Methods:Additional information on experimental techniques Legends: describing supplementary figures
View article: Supplementary Figure S10 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S10 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S10 4882K, Figure S10a and S10b: Nuclear beta-catenin accumulation in human synovial sarcoma tumors
View article: Supplementary Figure S11 and Tables S1-S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S11 and Tables S1-S3 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S11 and Tables S1-S3 - PDF file 460K, Figure S11: Regulation of an embryonic Wnt-interactive network by SYT-SSX2 and in human synovial sarcomas Table S1: Differentially regulated Wnt components in mesenchymal precursor…
View article: Supplementary Figures S4 - S7 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figures S4 - S7 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figures S4, S5, S6, S7 - PDF file 1832K, Figure S4:Pyrvinium effect on beta-catenin in SYT-SSX2 expressing C2C12 and synovial sarcoma cells Figure S5:Phosphorylated �-catenin and full-length APC in HS-SY-II and SYO-1 SS cells…
View article: Supplementary Figure S8 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S8 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S8 - PDF file 1084K, Figure S8: Effects of SSTC-104 on Wnt-regulated tissues
View article: Supplementary Figure S1 from Targeting the Wnt Pathway in Synovial Sarcoma Models
Supplementary Figure S1 from Targeting the Wnt Pathway in Synovial Sarcoma Models Open
Supplementary Figure S1 - PDF file 554K, Breeding strategy used to generate beta-catenin-null SYT-SSX2 transgenic mice
View article: IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells
IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells Open
Chondrosarcoma is a group of primary bone cancers that arise from transformed cells of chondrocytic lineage. Tumor recurrence and metastasis are devastating for patients with chondrosarcoma since there are no effective treatment options. I…
View article: ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control
ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control Open
Synovial sarcoma is an aggressive malignancy with no effective treatments for patients with metastasis. The synovial sarcoma fusion SS18-SSX, which recruits the SWI/SNF-BAF chromatin remodeling and polycomb repressive complexes, results in…
View article: Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth Open
Chondrosarcomas are a heterogeneous group of malignant bone tumors that produce hyaline cartilaginous matrix. Mutations in isocitrate dehydrogenase enzymes (IDH1/2) were recently described in several cancers, including conventional and ded…